Elanco Animal Health (ELAN) Product Approval Issues Case

• $ELAN stockholders filed a claim against Elanco Animal Health for hiding delays in product approvals and safety risks tied to its key products.

• After the news on June 27, 2024, $ELAN dropped by over 20%.

• Elanco Investors can join this case to be notified about potential recovery.

Case Details:

Throughout late 2023 and early 2024, Elanco repeatedly assured investors that its products, Zenrelia and Credelio Quattro, would be approved in early 2024.

However, on June 27, 2024, Elanco revealed that Zenrelia’s U.S. approval would be delayed, with the FDA requiring a boxed warning about safety risks based on a study involving unvaccinated dogs.

The approval of Credelio Quattro was also pushed back to late 2024 due to regulatory setbacks.

After this news, $ELAN fell by over 20%.

Based on these events, $ELAN investors filed a claim against Elanco, accusing the company of the following:

• It failed to disclose safety risks associated with Zenrelia and misled investors about the expected U.S. approval timelines of Zenrelia and Credelio Quattro.

• Elanco also overstated financial prospects tied to these product launches.

Considering all the representations, investors suspect Elanco misled them about the risks and delays in its products approval process.